Literature DB >> 28982857

Effect of Hyperglycemia on Antitumor Activity and Survival in Tumor-bearing Mice Receiving Oxaliplatin and Fluorouracil.

Mai Ikemura1, Tohru Hashida2.   

Abstract

BACKGROUND/AIM: Diabetic patients are at a higher risk of carcinogenesis and death from cancer, including colorectal cancer, than healthy individuals. The efficacy of cancer chemotherapy in the diabetic condition remains unclear. In this study, we investigated the efficacy of anticancer agents oxaliplatin and fluorouracil in streptozotocin (STZ)-treated hyperglycemic mice.
MATERIALS AND METHODS: Starting 7 days after transplantation of colonic adenocarcinoma colon-26 cells, STZ-treated and control mice were intraperitoneally administered oxaliplatin, fluorouracil, and levofolinate (FOLFOX) every 2 weeks.
RESULTS: Tumor growth was delayed in STZ-treated mice compared to control mice. The tumor volume was significantly smaller after treatment with FOLFOX in control mice, but not in STZ-treated mice. Despite delayed tumor growth, and regardless of whether they received treatment, survival was shorter in STZ-treated mice than in control mice.
CONCLUSION: Cancer chemotherapy with oxaliplatin and fluorouracil was less effective and survival was shorter in hyperglycemia. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Diabetes; cancer chemotherapy; colorectal cancer; fluorouracil; hyperglycemia; oxaliplatin

Mesh:

Substances:

Year:  2017        PMID: 28982857     DOI: 10.21873/anticanres.11975

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  Hyperglycemia-induced oxidative stress promotes tumor metastasis by upregulating vWF expression in endothelial cells through the transcription factor GATA1.

Authors:  Han-Seok Jeong; Da-Hye Lee; Seung-Hoon Kim; Chang-Han Lee; Hyun Mu Shin; Hang-Rae Kim; Chung-Hyun Cho
Journal:  Oncogene       Date:  2022-01-29       Impact factor: 8.756

2.  Hyperglycemia-Associated Dysregulation of O-GlcNAcylation and HIF1A Reduces Anticancer Action of Metformin in Ovarian Cancer Cells (SKOV-3).

Authors:  Aneta Rogalska; Ewa Forma; Magdalena Bryś; Agnieszka Śliwińska; Agnieszka Marczak
Journal:  Int J Mol Sci       Date:  2018-09-13       Impact factor: 5.923

3.  Hyperglycemia Promotes Chemoresistance Through the Reduction of the Mitochondrial DNA Damage, the Bax/Bcl-2 and Bax/Bcl-XL Ratio, and the Cells in Sub-G1 Phase Due to Antitumoral Drugs Induced-Cytotoxicity in Human Colon Adenocarcinoma Cells.

Authors:  Loredana Bergandi; Eleonora Mungo; Rosa Morone; Ornella Bosco; Barbara Rolando; Sophie Doublier
Journal:  Front Pharmacol       Date:  2018-08-13       Impact factor: 5.810

4.  High blood sugar levels but not diabetes mellitus significantly enhance oxaliplatin chemoresistance in patients with stage III colorectal cancer receiving adjuvant FOLFOX6 chemotherapy.

Authors:  I-Ping Yang; Zhi-Feng Miao; Ching-Wen Huang; Hsiang-Lin Tsai; Yung-Sung Yeh; Wei-Chih Su; Tsung-Kun Chang; Se-Fen Chang; Jaw-Yuan Wang
Journal:  Ther Adv Med Oncol       Date:  2019-08-20       Impact factor: 8.168

5.  The GLP-1R Agonist Exendin-4 Attenuates Hyperglycemia-Induced Chemoresistance in Human Endometrial Cancer Cells Through ROS-Mediated Mitochondrial Pathway.

Authors:  Yu Zhang; Juan Cheng; Jing Li; Junxian He; Xiaomao Li; Fen Xu
Journal:  Front Oncol       Date:  2021-12-20       Impact factor: 6.244

Review 6.  Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents.

Authors:  Jelena Vekic; Aleksandra Zeljkovic; Aleksandra Stefanovic; Rosaria Vincenza Giglio; Marcello Ciaccio; Manfredi Rizzo
Journal:  Int J Mol Sci       Date:  2021-11-17       Impact factor: 6.208

Review 7.  High glucose: an emerging association between diabetes mellitus and cancer progression.

Authors:  Suangson Supabphol; Wunchana Seubwai; Sopit Wongkham; Charupong Saengboonmee
Journal:  J Mol Med (Berl)       Date:  2021-05-26       Impact factor: 4.599

8.  A novel patient-derived orthotopic xenograft (PDOX) mouse model of highly-aggressive liver metastasis for identification of candidate effective drug-combinations.

Authors:  Zhiying Zhang; Kaiwen Hu; Kentaro Miyake; Tasuku Kiyuna; Hiromichi Oshiro; Sintawat Wangsiricharoen; Kei Kawaguchi; Takashi Higuchi; Sahar Razmjooei; Masuyo Miyake; Sant P Chawla; Shree Ram Singh; Robert M Hoffman
Journal:  Sci Rep       Date:  2020-11-18       Impact factor: 4.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.